Male Breast Carcinoma Terminated Phase 3 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0030384 (Male Breast Carcinoma)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00520975Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEUTreatment